Summit Therapeutics Flags Going Concern Risk Over Cash Needs

Summit Therapeutics Inc. (NASDAQ:SMMT) on Thursday reported an adjusted loss of 19 cents, better than the consensus loss of 28 cents per share.

Benzinga • 12 hours ago

SMMT's Q2 Loss Wider Than Expected, Ivonescimab Development in Focus

Summit posts a wider Q2 loss with no revenues as ivonescimab advances through late-stage studies, undergoes FDA review & gains new development collaborations.

Zacks Investment Research • 13 hours ago

Summit Therapeutics Q2 Earnings Call Highlights

Summit Therapeutics NASDAQ: SMMT executives used the company's latest earnings call to emphasize updated survival data for ivonescimab, outline the timing of key late-stage trial readouts and detail the company's cash position as it prepares for a potential U.S. regulatory decision later this year.

MarketBeat • Jul 23, 2026

Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript

Summit Therapeutics Inc. (SMMT) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 24, 2026

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the second quarter and six months ended June 30, 2026 and provided an update on clinical and operational progress. “The clinical momentum of ivonescimab continues to build, with two recent key data readouts that significantly bolster our development progress. At ASCO, the landmark HARMONi-6 results established the first head-to-head Phase III study in any tumor type to demonstrate a meaningf.

Business Wire • Jul 23, 2026

SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study

Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development.

Zacks Investment Research • Jul 23, 2026

Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug

Summit Therapeutics Inc. (NASDAQ:SMMT) on Wednesday shared updated overall survival (OS) data from its Phase 3 HARMONi study, evaluating the investigational bispecific antibody ivonescimab for treating specific forms of lung cancer.

Benzinga • Jul 22, 2026

Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced results of an updated overall survival (OS) analysis from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. Ivonescimab plus platinum-doublet chemotherapy in this trial continues to show a positive OS trend and a consistent efficacy and safety profile in Asian and western patients when compared to chemotherapy alone. The HARMONi.

Business Wire • Jul 22, 2026

Summit Therapeutics: 'Buy' On Ivonescimab's November PDUFA And Impressive Partner Data

Summit Therapeutics is upgraded from 'Hold' to 'Buy' following FDA acceptance of its BLA for ivonescimab + chemotherapy in EGFR-mutant NSCLC. SMMT's OS data in the HARMONi phase 3 trial improved over time, with hazard ratios dropping from 0.79 to 0.76 in both Western and ITT populations. Akeso's HARMONi-6 trial showed ivonescimab + chemo achieved a 34% reduction in risk of death versus tislelizumab + chemo in 1st-line NSCLC.

Seeking Alpha • Jul 22, 2026

These major drug stocks rally after Trump's zero tariff announcement

President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.

Finbold • Jul 22, 2026